Antipsychotic Prescribing: Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• LectureClozapine Basics

  Oliver Freudenreich

  Introductory overview of the fundamentals of using clozapine in clinical practice.

  ClozapineSchizophrenia & Psychosis

• LecturePharmacology of Antipsychotic Drugs

  Frank Tarazi

  Covers the pharmacology of antipsychotic drugs, including how they act and how their properties differ.

  Neuroscience & Mechanisms

• LectureClinical Vignettes with Question & Answer

  Oliver Freudenreich

  Case-based vignettes illustrating practical clozapine management, followed by audience questions and answers.

  Clozapine

• LectureFirst-Episode Psychosis and Schizophrenia

  Oliver Freudenreich

  Early intervention and pharmacologic management of first-episode psychosis and schizophrenia.

  Schizophrenia & Psychosis

• LectureManagement of Side-Effects of Antipsychotics

  Abigail Donovan

  Preventing and treating the metabolic, motor, and other adverse effects of antipsychotic medications.

  GLP-1 & Metabolic PsychiatryTardive Dyskinesia & Movement Disorders

See all 7 antipsychotic prescribing sessions at this meeting →

MasterPsych Psychiatry Conference 2026

October 19–22, 2026 · Newport Beach, CA

• LectureSchizoaffective Disorders: Treatment Update

  Adrian Preda

  Current diagnostic and treatment considerations for schizoaffective disorder.

  Bipolar DisorderSchizophrenia & Psychosis

• LectureSchizophrenia: Treatment Update

  Rimal Bera

  An update on current schizophrenia pharmacotherapy.

  Schizophrenia & Psychosis

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• LecturePsychopharmacological Management of Irritability, Impulsive Aggression, and Self-Injurious Behaviors in Youth With ASD

  Alice R. Mao

  Reviews medication strategies for irritability, aggression, and self-injury in youth with autism.

  Autism & Neurodevelopmental DisordersChild & Adolescent

• LectureRecent Pharmacogenetic Data With a Focus on Antipsychotic Medications

  Laura B. Ramsey

  Presents recent pharmacogenetic findings relating to antipsychotic medications in young patients.

  Child & AdolescentPharmacogenomics & Precision Psychiatry

• LectureFollowing the Evidence: Guidelines and Resources to Inform the Use of Pharmacogenomics in Antipsychotic Prescribing

  Jeffrey R. Bishop

  Covers available guidelines and resources that help clinicians apply pharmacogenomic information when prescribing antipsychotics.

  Child & AdolescentPharmacogenomics & Precision Psychiatry

• LectureEvidence-Based Strategies to Screen and Manage Endocrine and Metabolic Complications

  Sadiq Naveed

  Reviews screening and management of endocrine and metabolic complications of psychotropic medications in children and adolescents.

  Child & AdolescentGLP-1 & Metabolic Psychiatry

• CoursePediatric Psychopharmacology and Neurotherapeutics: The When and How of Initiating and Discontinuing Interventions

  Robyn P. Thom · Neera Ghaziuddin · Graham J. Emslie · Robert L. Findling · Raman Baweja · Bekir B. Artukoglu · Lee Wachtel

  Institute organized around starting and stopping treatment across antidepressants, antipsychotics, and stimulants, plus pediatric ECT and the psychotherapeutic dimensions of prescribing, with faculty including Graham Emslie and Robert Findling.

  Child & AdolescentDeprescribing & PolypharmacyNeuromodulation (ECT, TMS)

See all 25 antipsychotic prescribing sessions at this meeting →

NEI Fall Congress 2026

November 5–8, 2026 · Colorado Springs, CO

• SymposiumShould I Stay or Should I Go? Using Dopamine Receptor Blocking Agents in Pediatrics

  Jeffrey Robert Strawn

  Weighs when to start, continue, or stop dopamine receptor blocking agents in pediatric patients, including safety and monitoring considerations.

  Child & AdolescentDrug Interactions & Safety

• SymposiumEfficacy, Acceptability, and Accessibility and Accessibility of SDA-PAs: Shared Decision Making in the Selection and Sequencing of Treatments for MDD

  Roger S. McIntyre · Thomas L. Schwartz

  Applies shared decision-making to selecting and sequencing serotonin-dopamine activity partial agonists among MDD treatment options. Title reproduced exactly as published on the agenda.

  Depression

• SymposiumTime Is Brain: Early Adoption of Long-Acting Injectables to Improve Functional Outcomes in Serious Mental Illness

  Christoph U. Correll

  Makes the case for earlier use of long-acting injectable antipsychotics in serious mental illness, with shared decision-making strategies.

  Long-Acting InjectablesSerious Mental Illness

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• Oral abstractSubstance Use and Outcomes following Intramuscular Antipsychotic Treatment for Acute Pediatric Agitation: A Retrospective Cohort Study

  Angelo Chaia

  Retrospective study of outcomes after intramuscular antipsychotics for pediatric agitation, by substance use status.

  Child & AdolescentEmergency & Acute PsychiatrySubstance Use Disorders

• PosterSevere Gambling Disorder Precipitated by Compounded Cyp Inhibition from Kratom and an Ssri in a Patient on Low-Dose Aripiprazole: A Novel Three-Way Pharmacokinetic Interaction

  Zakariya Irfanullah

  Case of gambling disorder attributed to a kratom, SSRI and aripiprazole interaction.

  Drug Interactions & SafetySubstance Use Disorders

NPA 32nd Annual Psychopharmacology Update 2027

February 10–13, 2027 · Las Vegas, NV

• LectureEmergency Psychopharmacology

  Kimberly Nordstrom

  Pharmacologic management of agitation and other psychiatric emergencies in acute settings.

  Emergency & Acute Psychiatry

• LectureUsing GLP-1s in Psychiatry

  Roger S. McIntyre

  Where GLP-1 receptor agonists fit in psychiatric practice, from antipsychotic-associated weight gain to emerging behavioral indications.

  GLP-1 & Metabolic Psychiatry

• LectureDelirium

  Jose Maldonado

  Recognition, workup, and management of delirium, including when and how to use antipsychotics.

  Dementia & Cognitive DisordersMedical Comorbidity & C-L Psychiatry

39th ECNP Congress

October 10–13, 2026 · Munich, Germany

• SessionRS – Regulatory Spotlight Session – Metabolic risks of psychiatric medications: improving clinical safety through regulatory, industry, and academic insights

  Margaret Hahn · Vikas Mohan Sharma · Katarina Vucic

  Academic, industry, and regulator perspectives on managing metabolic risks of psychotropic medications.

  Drug Interactions & SafetyGLP-1 & Metabolic Psychiatry

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• LectureComplex Psychopharmacology in Bipolar Disorder: Combination Therapy, Dosing Pearls & Side-Effect Navigation

  Joseph Goldberg

  Advanced guidance on sequencing lithium, anticonvulsants, and atypical antipsychotics in bipolar disorder, with case vignettes on inadequate response, intolerability, and polypharmacy.

  Bipolar DisorderDeprescribing & PolypharmacyLithium & Mood Stabilizers

• SymposiumMasterClass: Across Mood Episodes and Throughout the Lifespan: Atypical Antipsychotic Strategies for MDD and Bipolar Disorder

  Gregory Mattingly · Desiree Matthews

  Case-driven review of selecting atypical antipsychotics across mood episodes, weighing efficacy, tolerability, adherence, and patient-specific factors.

  Bipolar DisorderDepression

• LectureTreatment-Resistant Bipolar Depression: Sequencing, Switching & Advanced Strategies

  Michael Thase

  Step-by-step algorithms for treatment-resistant bipolar depression — when to switch, augment, or combine — with evidence on newer agents such as lumateperone, cariprazine, and ketamine.

  Bipolar DisorderKetamine & Esketamine

• SymposiumMasterClass: Operationalizing Adherence: A Practical Guide to LAI Integration in Schizophrenia Care

  Megan Ehret · Jaden Todd · Emma Nelson · Ilan Melnick · Amber Hoberg · Kevin Williams

  Compares available long-acting injectable antipsychotic formulations and offers patient-centered communication and logistics strategies for initiating, administering, and reintroducing LAIs.

  Long-Acting InjectablesSchizophrenia & Psychosis

• DebateWhen Standard Treatment Isn't Enough: Complex Schizophrenia Cases and Clinical Decision-Making

  Leslie Citrome · Erin Crown · Brooke Kempf

  Panel works through challenging schizophrenia cases involving treatment resistance and functional decline, covering sequencing, clozapine timing, augmentation, and metabolic and sedation trade-offs.

  ClozapineGLP-1 & Metabolic PsychiatrySchizophrenia & Psychosis